1.065

3.93% 0.035

Bluejay Diagnostics Inc (BJDX)

Überblick Nachrichten Preisverlauf Financials Warum fällt BJDX? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$1.03

Offen:

$1.01

24-Stunden-Volumen:

366.15K

Relative Volume:

0.07

Marktkapitalisierung:

$1.10M

Einnahmen:

Nettoeinkommen (Verlust:

$-6.90M

KGV:

-0.076

EPS:

-14.0152

Netto-Cashflow:

$-6.65M

1W Leistung:

+26.07%

1M Leistung:

+0.05%

6M Leistung:

-42.75%

1J Leistung:

-81.28%

1-Tages-Spanne:

$1.00

$1.08

1-Wochen-Bereich:

$0.82

$1.09

52-Wochen-Spanne:

$0.818

$16.68

Bluejay Diagnostics Inc Stock (BJDX) Company Profile

Firmenname

Bluejay Diagnostics Inc

Sektor

Healthcare (1087)

Branche

Medical Devices (141)

Telefon

(978) 631-0152

Adresse

360 MASSACHUSETTS AVENUE, SUITE 203, ACTON

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

BJDX's Discussions on Twitter

Compare BJDX vs ABT, MDT, SYK, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BJDX Bluejay Diagnostics Inc	1.065	1.07M	0	-6.90M	-6.65M	-14.02
ABT Abbott Laboratories	105.64	182.59B	46.59B	5.41B	7.38B	3.0938
MDT Medtronic Plc	92.50	118.18B	36.36B	4.84B	5.43B	3.7261
SYK Stryker Corp	275.17	106.03B	25.27B	3.34B	4.57B	8.6334
BSX Boston Scientific Corp	45.79	65.19B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	86.50	49.99B	6.30B	1.07B	1.09B	1.8406

Bluejay Diagnostics Inc Aktie (BJDX) Neueste Nachrichten

Sep 08, 2026

Bluejay Diagnostics expands federal access via Lovell partnership - TipRanks

Sep 08, 2026

Bluejay Diagnostics Taps Lovell Government Services as Exclusive SDVOSB Distributor for U.S. Government - TradingView

Sep 08, 2026

Bluejay Diagnostics Federal Healthcare Partnership Builds Commercial Pathway Ahead of FDA Clearance - Yahoo Finance

Sep 08, 2026

Bluejay Diagnostics, Inc. and Lovell Government Services, Inc. Announce Partnership to Expand Access to U.S. Federal Healthcare Markets - marketscreener.com

Sep 08, 2026

Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets - marketscreener.com

Sep 08, 2026

Sep 07, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 07, 2026

Aug 31, 2026

NASDAQ Stocks Under $1: FNGR, DUO, EPOW, CYAB in Focus Now! - FinancialContent

Aug 31, 2026

Aug 28, 2026

BJDX Stock Draws Traders As Sepsis Test Milestones Hit - StocksToTrade

Aug 28, 2026

Aug 20, 2026

Armistice Capital Acquires 142,728 Shares of Bluejay Diagnostics Inc (BJDX) - GuruFocus

Aug 20, 2026

Aug 18, 2026

Bluejay (BJDX) Session-Level Review: Loses 4.90% to Close at $0.97 at the Close; Reference Levels: the Session Ends Within the Reported Technical Boundaries for the Current SessionGrowth ETF - vinanet.vn

Aug 18, 2026

Bluejay Diagnostics (BJDX) links director options to FDA nod - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (BJDX) links director’s 100K options to FDA clearance - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (BJDX) ties director’s options to FDA device clearance - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (NASDAQ: BJDX) insider updates share holdings - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (NASDAQ: BJDX) ties director options to FDA clearance - Stock Titan

Aug 18, 2026

Aug 14, 2026

Armistice Capital discloses 9.99% Bluejay Diagnostics (BJDX) position in Schedule 13G - Stock Titan

Aug 14, 2026

Aug 13, 2026

Bluejay Diagnostics (BJDX) investor group discloses 9.99% ownership with warrants - Stock Titan

Aug 13, 2026

Form 8K Bluejay Diagnostics Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

Bluejay Advances Symphony Platform, Strengthens Cash Position - TipRanks

Aug 13, 2026

Form 8K Bluejay Diagnostics Inc For: 13 August - Investing.com India

Aug 13, 2026

Bluejay Diagnostics Q2 Results: EPS loss narrows 80% YoY to $(1.12) - scanx.trade

Aug 13, 2026

Bluejay Diagnostics completes enrollment in sepsis test study - Investing.com

Aug 13, 2026

Bluejay Diagnostics completes enrollment in sepsis test study By Investing.com - Investing.com Australia

Aug 13, 2026

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization - The Manila Times

Aug 13, 2026

Bluejay Diagnostics Completes Enrollment in SYMON-II Pivotal Study, Advances Toward 510(k) Submission and Commercialization - quiverquant.com

Aug 13, 2026

Bluejay completes 750-patient study enrollment for Symphony IL-6 - Stock Titan

Aug 13, 2026

Aug 12, 2026

Bluejay Diagnostics, Inc. Q2 2026: Net loss $(2.32M), EPS $(1.12) — 10-Q Summary - TradingView

Aug 12, 2026

Bluejay Diagnostics (BJDX) warns on going concern and Nasdaq listing risk - Stock Titan

Aug 12, 2026

Aug 07, 2026